---
title: Media Coverage and Research Articles
layout: page
description: 'Read about Evusheld in the media.'
image: assets/images/media.png
nav-menu: true
---
## Media Coverage
These are articles in mainstream media/press releases, in reverse chronological order.

* ‘Evusheld Significantly Prevented COVID-19 Disease Progression or Death in Tackle Phase III Treatment Trial’. 2022. _Zawya_. 10 June 2022. https://www.zawya.com/en/press-release/companies-news/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial-appg120c.
* ‘AstraZeneca’s Evusheld Prevents Disease Progression in Phase III Covid-19 Trial’. 2022. _Clinical Trials Arena_ (blog). 9 June 2022. https://www.clinicaltrialsarena.com/news/astrazeneca-evusheld-covid-trial-2/.
* AstraZeneca. 2022. ‘Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial’. 8 June 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html.
* Chudleigh, Hannah. 2022. ‘AstraZeneca’s Evusheld Successfully Prevents Progression to Severe COVID-19’. _BioSpace_. 8 June 2022. https://www.biospace.com/article/astrazeneca-s-evusheld-successfully-prevents-progression-to-severe-covid-19-/.
* Sharp, Christopher. 2022. ‘Covid: Why the Threat of the Virus Still Haunts Those Are Are Immunosuppressed’. Express, 29 May 2022. https://www.express.co.uk/life-style/health/1615894/covid-kidney-disease-immunosuppressed-exclusive/amp
* Kollewe, Julia. 2022. ‘AstraZeneca Boss Calls for UK to Provide New Covid-19 Medicine to the Vulnerable’. _The Guardian_, 29 April 2022, sec. Business. https://www.theguardian.com/business/2022/apr/29/evusheld-covid-19-medicine-astrazeneca-immunosuppressed-vulnerable-uk.
* Ennals, Ethan. 2022. ‘Covid 19: Vulnerable Patients Denied £800 Anti-Viral Jab Unless They Go Private’. Daily Mail. 23 April 2022. https://www.dailymail.co.uk/health/article-10746187/Covid-19-Vulnerable-patients-denied-800-anti-viral-jab-unless-private.html.
* AstraZeneca. 2022. ‘Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants Including BA.2 in New Independent Studies’. 21 March 2022. https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html.
* AstraZeneca. 2022. ‘AstraZeneca’s Antibody Combination, Evusheld (Tixagevimab Co-Packaged with Cilgavimab) Authorised for Use in Great Britain for Pre-Exposure Prophylaxis (Prevention) of COVID-19’. 17 March 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html.

## Research Articles, Preprints, and Policy Documents
These are formal research studies demonstrating the efficacy of Evusheld. These are arranged by alphabetical order of first author.

Articles marked [PREPRINT] have not necessarily been subject to [peer review](https://en.wikipedia.org/wiki/Peer_review).

* NHS England RAPID-C19. 2022. ‘Defining the Highest-Risk Clinical Subgroups upon Community Infection with SARS-CoV-2 When Considering the Use of Neutralising Monoclonal Antibodies (NMABs) and Antiviral Drugs: Independent Advisory Group Report’. _GOV.UK_. 30 May 2022. https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies.
* Stuver, Robert, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, et al. 2022. ‘Activity of AZD7442 (Tixagevimab-Cilgavimab) against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies’. _Cancer Cell_, May. https://doi.org/10.1016/j.ccell.2022.05.007.
* Montgomery, Hugh, F. D. Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, et al. 2022. ‘Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19 (TACKLE): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial’. _The Lancet Respiratory Medicine_. https://doi.org/10.1016/S2213-2600(22)00180-1.
* [PREPRINT] Tuekprakhon, Aekkachai, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen M. Ginn, Muneeswaran Selvaraj, et al. 2022. ‘Further Antibody Escape by Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum’. _bioRxiv_. https://doi.org/10.1101/2022.05.21.492554.
* Yamasoba, Daichi, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, and Kei Sato. 2022. ‘Neutralisation Sensitivity of SARS-CoV-2 Omicron Subvariants to Therapeutic Monoclonal Antibodies’. _The Lancet Infectious Diseases_. https://doi.org/10.1016/S1473-3099(22)00365-6.
* [PREPRINT] Young-Xu, Yinong, Lauren Epstein, Vincent C. Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, and Adit A. Ginde. 2022. ‘Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data’. _medRxiv_. https://doi.org/10.1101/2022.05.28.22275716.

## Events
* AstraZeneca. 2022. ‘The Unmet Needs of Immunocompromised Patients Post-COVID 19’. _POLITICO_. 9 June 2022. https://www.politico.eu/event/the-unmet-needs-of-immunocompromised-patients-post-covid-19/.
